Pooled Survival and Response Data From Phase III Randomized Controlled Trials for Gemcitabine-based Regimes in the Treatment of Advanced Pancreatic Cancer (Q33855365)

From Wikidata

Jump to navigation Jump to search

scientific article published on August 1, 2013

Language	Label	Description	Also known as
English	Pooled Survival and Response Data From Phase III Randomized Controlled Trials for Gemcitabine-based Regimes in the Treatment of Advanced Pancreatic Cancer	scientific article published on August 1, 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Pooled Survival and Response Data From Phase III Randomized Controlled Trials for Gemcitabine-based Regimes in the Treatment of Advanced Pancreatic Cancer (English)

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

phase III clinical trial

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

Ashley R Dennison

7

object named as

Ashley R. Dennison

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21436672

28 November 2024

author name string

Ali Arshad

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Dhya Al-Leswas

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Omer Al-Taan

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

James Stephenson

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Matthew Metcalfe

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

William P. Steward

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21436672

28 November 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21436672

28 November 2024

publication date

1 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

August 2013

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21436672

28 November 2024

full work available at URL

http://journals.lww.com/00000421-201308000-00017

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

American Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

36

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

411-414

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

3

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

5

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer

6

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

7

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

8

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

9

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology

10

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

11

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

12

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

13

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

14

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

15

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

16

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

17

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

18

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

19

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

20

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study

21

1 reference

10.1097/COC.0B013E3182124216

https://api.crossref.org/works/10.1097/COC.0B013E3182124216

28 November 2024

Identifiers

10.1097/COC.0B013E3182124216

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33855365&oldid=2280637493"